OncoSec Medical Appoints Dr. Soldano Ferrone to Scientific Advisory Board
25 June 2014 - 8:02PM
Business Wire
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its
ImmunoPulse DNA-based intratumoral cancer immunotherapy, has
appointed Dr. Soldano Ferrone, M.D., Ph.D., to the company’s
Scientific Advisory Board. Dr. Ferrone is an internationally
renowned expert in tumor immunology, and will contribute his
considerable expertise to the company as it works to advance an
expanding intratumoral immunotherapy pipeline.
Dr. Ferrone’s research program focuses on the characterization
of escape mechanisms deployed by tumor cells to avoid
immune-mediated recognition and destruction. He has also studied
how combined immunotherapeutic strategies can counteract these
tumor escape mechanisms. These studies are greatly facilitated by
the large panel of HLA antigen- and human tumor antigen-specific
monoclonal antibodies he has developed and shared with the
scientific community over the years.
He has described the results of his studies in more than 600
papers published in peer-reviewed journals. Moreover he has been
the editor of 14 books and the guest editor of five special issues
of oncology journals.
“Dr. Ferrone brings considerable expertise to our growing panel
of distinguished experts and key opinion leaders,” said Punit
Dhillon, President and CEO. “We believe his guidance will prove
invaluable as we work to advance our immune oncology pipeline and
establish OncoSec as a leader in intratumoral immunotherapy.”
Dr. Ferrone received his M.D. and Ph.D. degrees in 1964 and in
1971, respectively, from the University of Milan, Milan, Italy. He
has held faculty positions at the University of Milan, Scripps
Clinic and Research Foundation, La Jolla, CA, Columbia University,
New York, NY, New York Medical College, Valhalla, NY, Roswell Park
Cancer Institute, Buffalo, NY and at the University of Pittsburgh
School of Medicine, Pittsburgh, PA. Since 2012 he has been a
faculty member of the Department of Surgery at Massachusetts
General Hospital, Harvard Medical School, Boston, MA.
Dr. Ferrone has received numerous awards and honors. For the
last 30 years he has been a member of many review committees
including NIH Study Sections, and of the editorial boards of many
scientific journals. Furthermore he is a member of several external
scientific advisory boards.
“Long before immuno-oncology was recognized as an important
field, Soldano was in the forefront of the attempt to understand
how tumors subvert the immune system — particularly, how they
disrupt normal mechanisms of antigen processing and presentation,”
said Dr. Robert Pierce, M.D., Chief Medical Officer. “We believe
Soldano’s expertise will help us further define the mechanism by
which intratumoral electroporation of IL-12 leads to a reversal of
these pathologic defects and augments immunogenicity.”
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse immunotherapy to treat solid tumors. OncoSec
Medical's core technology leverages a proprietary electroporation
platform to enhance the local delivery and uptake of
IL-12 and other DNA-based immune-modulating agents. Clinical
studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response without the systemic toxicities
associated with other treatments. OncoSec's clinical programs
currently include three Phase 2 trials targeting metastatic
melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. As
the company continues to evaluate ImmunoPulse in these indications,
it is also investigating additional indications and combination
therapeutic approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
Investor Relations:OncoSec Medical Inc.Veronica Vallejo,
CFO855-662-6732investors@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2024 to May 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From May 2023 to May 2024